HARROW, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 10.53 USD | +5.30% |
|
+0.77% | -5.98% |
| 04-11 | Craig-Hallum Starts Harrow With Buy Rating, $24 Price Target | MT |
| 03-22 | B. Riley Securities Adjusts Harrow Health's Price Target to $26 From $30, Maintains Buy Rating | MT |
| Sales 2024 * | 185M 14.79B | Sales 2025 * | 251M 20.12B | Capitalization | 372M 29.81B |
|---|---|---|---|---|---|
| Net income 2024 * | -12M -961M | Net income 2025 * | 23M 1.84B | EV / Sales 2024 * | 2.02 x |
| Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 1.48 x |
| P/E ratio 2024 * |
-32.7
x | P/E ratio 2025 * |
17.7
x | Employees | 315 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 85.41% |
More Fundamentals
* Assessed data
More news
Latest transcript on Harrow, Inc.
More recommendations
More press releases
| 1 day | +5.30% | ||
| 1 week | +0.77% | ||
| Current month | -20.41% | ||
| 1 month | -16.30% | ||
| 3 months | +8.44% | ||
| 6 months | -23.58% | ||
| Current year | -5.98% |
1 week
9.86
11.23
1 month
9.8613.72
Current year
9.1313.72
1 year
7.6028.25
3 years
5.4028.25
5 years
3.3328.25
10 years
1.3528.25
| Managers | Title | Age | Since |
|---|---|---|---|
Mark Baum
CEO | Chief Executive Officer | 51 | 31/12/05 |
Andrew Boll
DFI | Director of Finance/CFO | 41 | 30/11/11 |
Jamie Webb
IRC | Investor Relations Contact | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Mark Baum
CEO | Chief Executive Officer | 51 | 31/12/05 |
| Director/Board Member | 65 | 01-25 | |
Adrienne Graves
BRD | Director/Board Member | 69 | 01-25 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.00% | 34 M€ | +2.14% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/04/24 | 10.53 | +5.30% | 608,714 |
| 25/04/24 | 10 | -2.63% | 449,827 |
| 24/04/24 | 10.27 | -0.48% | 406,228 |
| 23/04/24 | 10.32 | -2.64% | 661,080 |
| 22/04/24 | 10.6 | +1.44% | 587,408 |
Delayed Quote OTC Markets, April 26, 2024 at 09:00 pm
More quotes
Harrow, Inc. is an eyecare pharmaceutical company. The Company is engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the United States market. It provides a comprehensive portfolio of prescription and non-prescription pharmaceutical products. It owns commercial rights to portfolios of branded ophthalmic pharmaceutical products in North America, all of which are marketed under the Harrow name. It owns and operates ImprimisRx, an ophthalmology-focused pharmaceutical-compounding business. It owns United States commercial rights to various products: IHEEZO, VEVYE, TRIESENCE, VIGAMOX, ILEVRO, FLAREX, NATACYN, ZERVIATE and others. VIGAMOX (moxifloxacin hydrochloride ophthalmic solution) 0.5%, a fluoroquinolone antibiotic eye drops for the treatment of bacterial conjunctivitis caused by susceptible strains of organisms. IHEEZO (chloroprocaine hydrochloride ophthalmic gel) 3% is a low-viscosity gel indicated for ocular surface anesthesia.
Sector
Pharmaceuticals
Calendar
12/05/2024
- Q1 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C-
Sell
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
10.53
USD
Average target price
26.65
USD
Spread / Average Target
+153.09%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -5.98% | 372M | |
| +25.83% | 661B | |
| +27.00% | 566B | |
| -6.76% | 352B | |
| +20.34% | 332B | |
| +3.00% | 283B | |
| +13.09% | 231B | |
| +5.46% | 200B | |
| -9.61% | 195B | |
| -6.26% | 145B |
- Stock Market
- Equities
- HROW Stock
